Anti-HBV effect of liposome-encapsulated matrine in vitro and in vivo

Table 1 Inhibitory effect of Lip-M on secretion of HBsAg, HBeAg in 2.2.15 cell line.

Drug	TC50 (mg/mL)	HBsAg		HBeAg
		IC50 (mg/mL)	TI	IC50 (mg/mL)	TI
Lip-M	7.29	0.078	93.46	3.35	2.17
Matrine	1.33	<0.078	>17.05	>10	<0.13
Liposome	>10	>10	1	>10	1

Table 2 Inhibitory effect of Lip-M on DHBV-DNA level in vivo (mean±SD).

Group	Duck n	A value
		T0	T5	T10	T15	T20	P3
Control	5	1.07±0.19	1.39±0.33	0.98±0.29	0.97±0.30	0.95±0.27	0.89±0.18
Lip-M 20 mg/kg	6	0.95±0.18	1.08±0.21	0.43±0.22bde	0.40±0.12bde	0.22±0.10bde	0.20±0.10bde
Lip-M 10 mg/kg	6	0.95±0.38	1.07±0.68	0.75±0.33	0.68±0.34	0.56±0.26ac	0.55±0.25ac
Matrine 20 mg/kg	6	1.08±0.38	1.22±0.40	0.79±0.19	0.73±0.24	0.55±0.32ac	0.59±0.35ac

^aP<0.05,

^bP<0.01 vs the control;

^cP<0.05,

^dP<0.01 vs level of the group at different times (T₁₀, T₁₅, T₂₀, P₃ ) after and before treatment(T₀);

^eP<0.05 vs group of matrine (20 mg/Kg).